Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Lucile Awad"'
Autor:
Lucile Awad, Sergei Tjulandin, Miguel Fodor, Eric Van Cutsem, Edouard Voznyi, Vladimir Moiseyenko, Manuel Constenla, Corrado Boni, Yee Chao, Jaffer A. Ajani, Alejandro Majlis, Adriano Rodrigues
Publikováno v:
Journal of Clinical Oncology. 25:3210-3216
Purpose Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline. Using validated instruments, we prospectively ass
Autor:
Jean-Yves Douillard, Gary Elfring, May Alakl, Gabriela Gruia, Langdon L. Miller, Lucile Awad, Paula K. Locker, Leonard B. Saltz, Nicoletta Pirotta
Publikováno v:
The Oncologist. 6:81-91
Background. Irinotecan is a topoisomerase I inhibitor that prolongs survival in patients with colorectal cancer refractory to fluorouracil (5-FU) and leucovorin (LV). This demonstrated activity of irinotecan as effective second-line therapy for color
Autor:
Harry Bleiberg, Philippe Rougier, Gilles Freyer, Patrice Herait, Lucile Awad, Dominique Mignard, Véronique Trillet-Lenoir, J.P. Droz, Stéphane Culine, Michel Marty, Roland Bugat
Publikováno v:
British Journal of Cancer
Our purpose was to determine, in patients with metastatic colorectal carcinoma treated with irinotecan single-agent after 5-FU failure, the most significant predictive parameters for tumour response, progression-free survival and toxicity. Between Oc
Autor:
Joseph C. Carmichael, G. Gruia, P. Jandik, Timothy Iveson, Philippe Rougier, Lucile Awad, M. Alakl, Arnaud Roth, P. Karasek, Roger D James, David Cunningham, Jean-Yves Douillard, M. Navarro
Publikováno v:
The Lancet, Vol. 355, No 9209 (2000) pp. 1041-7
Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectal cancer.387 patients previously untreat
Autor:
Hans Starkhammar, Cornelis J. A. Punt, Seppo Pyrhönen, Tamas Hickish, C. Topham, Roger D James, Lucile Awad, Christian Jacques, Reino Heikkila, Tom Børge Johannesen, Patrice Herait, David Cunningham
Publikováno v:
The Lancet. 352:1413-1418
Summary Background In phase II studies, irinotecan is active in metastatic colorectal cancer, but the overall benefit has not been assessed in a randomised clinical trial. Methods Patients with proven metastatic colorectal cancer, which had progresse
Autor:
Dominique Méry-Mignard, Lucile Awad, David Cunningham, Emmanuel Mitry, E. Van Cutsem, Ph. Rougier, J.-Y. Douillard, E. Magherini
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 15(7)
Background: The infusional LV5FU2 and Arbeitsgemeinschaft Internische Onkologie (AIO) regimens are used widely in the treatment of advanced colorectal cancer. Irinotecan combined with these regimens increases survival in front-line treatment. Irinote
Publikováno v:
Advances in Survival Analysis
Publisher Summary This chapter shows how quality of life (QoL) can be analyzed by defining an event corresponding to its definitive deterioration. In quality-of-life analysis, missing data cannot be considered missing at random as they are most likel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcccff242a116817065f9ce47a797600
https://doi.org/10.1016/s0169-7161(03)23038-8
https://doi.org/10.1016/s0169-7161(03)23038-8
Publikováno v:
Statistical Methods for Quality of Life Studies ISBN: 9781441952073
In metastatic cancer studies, the deterioration of the patient’s health status is often observed during the trial either because of the toxicity of treatment or the progression of disease. This deterioration is very likely to be reflected in the pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9f37738ecaee07be02a46cd466097af
https://doi.org/10.1007/978-1-4757-3625-0_18
https://doi.org/10.1007/978-1-4757-3625-0_18
Autor:
Lucile Awad, Kurt Possinger, Norbert Niederle, Harry Bleiberg, Eric Van Cutsem, Rudolf Morant, Patrice Herait, Matilde Navarro, Emilio Bajetta, Roberto Labianca, Philippe Rougier, Christian Jacques, Jacques Wils
Publikováno v:
Lancet (London, England). 352(9138)
Summary Background In phase II trials, irinotecan is active in patients with advanced colorectal cancer, but the survival and clinical benefit of irinotecan compared with secondline fluorouracil by continuous infusion is not known. Methods 267 patien
Publikováno v:
Archives of environmental health. 39(1)
The counts of ferruginous bodies (pulmonary-coated mineral fibers) in sputum samples from inhabitants in each of the two agricultural villages of Karain and Tuskoy (Cappadocia, central Turkey) increased with subjects' age, whereas 94% of samples coll